Orphan drug company Swedish Orphan International (SOI) will be moving to bespoke new offices in Cambridge this summer.
The company says that the new environment will provide an appropriate infrastructure to enable SOI to bring more orphan drugs to market and so improve the lives of many more patients with rare diseases.
Bruce Faulkner-Dunkley, the UK Managing Director, explains the difference this new location will make: “Although ‘orphan diseases’ affect no more than five in every 10,000 people, these illnesses are life-threatening and chronically debilitating. We at Swedish Orphan in the UK are committed to making a difference and ensuring that physicians are aware that the products are available, and working with the different patient organisations to ensure that patients gain access to these life-changing medications.
“Being in surroundings which are professional and designed for our purposes will enable the team at Swedish Orphan International to bring more drugs to market more efficiently in the UK.”
SOI aims to provide patients, healthcare professionals and the pharmaceutical industry with a global network specialising in the development, marketing and distribution of orphan drugs for the treatment of rare disorders, and products and services to satisfy unmet medical needs.
The company’s current portfolio includes Orfadin (nitisinone) for Hereditary Tyrosinaemia type 1 (HT-1), Ammonaps (sodium phenylbutyrate) for urea cycle disorders and
Ferriprox (deferiprone) for iron overload in patients with Thalassaemia major.